Cerebrolysin is a hydrolysate of a porcine brain which is used as a nootropic drug.

Cerebrolysin was discovered in 1949 in Austria and is used in medical practice since 1954. The drug has a broad range of indications including ischemic stroke, Alzheimer’s, Parkinson’s, dementia, traumatic brain injury, and ADHD in children.

The chemical composition of Cerebrolysin is pretty complex and consists of various neuropeptides, amino acids, and neurotrophic factors. One of the most important advantages of Cerebrolysin is its high tolerability in patients, as it rarely causes any side effects, high efficacy, and a wide spectrum of therapeutic action.

The official indications for use are:

  • Chronic cerebrovascular insufficiency
  • Ischemic stroke
  • Alzheimer’s disease
  • Dementia
  • Traumatic injuries of brain and spinal cord
  • Developmental delays in children
  • Attention deficit hyperactivity disorder in children
  • Antidepressant resistant depression

Dosage and administration

Doses below 5ml should be administered via intramuscular injection; higher doses should be taken via slow intravenous infusion.

Dosage and the treatment duration depend on the patient’s condition. The drug can be administered one-time only in the dosage of up to 50ml; however, a continuous course is more preferable. Recommended treatment course is daily injections for 10-20 days.

  • The dosage for acute conditions (ischemic stroke, TBI, neurosurgical complications) is 10-50ml.
  • Residual stage of stroke, traumatic brain injuries, and spinal cord injuries: 5-50ml.
  • Organic brain syndrome and depression: 5-30ml.
  • Alzheimer’s disease and vascular dementia: 5-30ml.
  • Pediatrics: 0.1-0.2ml per kg of body weight.

The course can be repeated for higher efficacy. After the first course, Cerebrolysin may be administered only 2-3 times a week.

Side effects

  • Side effects on gastrointestinal tract: loss of appetite, indigestion, diarrhea, constipation, nausea.
  • Central nervous system: agitation, insomnia.
  • Immune system: allergic reactions.
  • Reaction on administration: injecting the drug too fast may cause sweating, vertigo, and tachycardia.
  • Local Reactions: erythema, itching.
  • Other: arterial hypertonia, arterial hypotonia, fatigue, tremor, depression, apathy, common cold symptoms.

It should be noted that in clinical trials of Cerebrolysin, patients who received placebo also experienced adverse effects (agitation, arterial hypertonia, arterial hypotonia, fatigue, tremor, depression, apathy, headaches, dyspnea, diarrhea, and nausea) with the same frequency as Cerebrolysin group.


  • Acute renal insufficiency
  • Hypersensitivity
  • Epilepsy